Two distinct user profiles. They should run very different protocols.
BMI over 27, often over 30. Wants to lose meaningful body fat.
BMI in normal or near-normal range. Wants to optimize every metabolic marker.
A 39-amino acid synthetic peptide that activates three receptors at once. Half-life: about 6 days. Once-weekly dosing is what was studied.
Cuts intake. Reduces appetite and slows gastric emptying.
Supports insulin sensitivity, satiety, and adipocyte function.
Increases output. Raises energy expenditure and burns hepatic fat.
Two of the three reduce calories in. One increases calories out. That last piece is what nothing else on the market does.
Dose
Weight Loss % ★ Phase 3 TRIUMPH-4
28.7% mean weight loss at 68 weeks at 12 mg. The largest mean weight loss reported in any Phase 3 obesity trial.
This is the part that gets less attention but matters more for non-obese users. At 12 mg in Phase 2:
Triglycerides down by half or more at higher doses. hsCRP and other inflammatory markers improved. HbA1c down 0.4 percentage points in non-diabetics.
Insulin resistance, hepatic steatosis, and chronic inflammation are central nodes in the aging network. Retatrutide hits all of these directly.
Reduces AMPK, impairs autophagy, increases mTOR activity, raises oxidative stress.
Drives systemic insulin resistance. Associated with accelerated biological aging on methylation clocks.
Drives inflammatory cytokines. The fat you cannot see is the fat that kills you.
The strongest causal lipid marker for atherosclerosis. Retatrutide drops it 24%.
For someone optimizing for healthspan, this is more interesting than the scale number.
Used in every TRIUMPH trial. Almost certainly what the eventual label looks like. This protocol was designed for people with significant obesity. Lean users should not run this protocol.
2 mg weekly titration
Increase to 4 mg weekly
Increase to 6 mg weekly
9 mg then 12 mg or hold 9 mg
Maintenance dose was studied as a long-term lower-burden option. Hold at any step if tolerability requires it. Slower titration is not failure. It is smart dosing.
The most-argued question in the online community. Both work. The question is which suits you.
No punishing peaks, no end-of-week hunger spike.
Known efficacy. Known safety profile. No guesswork.
One day per week. Simple.
Doses are small enough that peaks are not punishing. Start here. Switch later if needed.
38% peak reduction. The smoothest blood levels possible.
More injections. More measurement error at small volumes. A 2-unit error on a 23-unit dose is 9% off. More friction with the protocol.
| Once-weekly | Twice-weekly | Three-times-weekly |
|---|---|---|
| 1 injection | 2 injections | 3 injections |
| 4:1 peak-to-trough ratio | 28% peak reduction | 38% peak reduction |
| Trial-validated | Most benefit with half the burden | Diminishing returns |
For most users, twice-weekly captures most of the benefit with half the injection burden.
The second most-argued question. The honest answer most people miss:
With a 6-day half-life, plasma concentration changes by less than 15% across 24 hours. There is no pharmacokinetically meaningful "best time."
The 2–4 hour window after injection is when nausea is at its peak. Pick whichever timing puts that window where it bothers you least. Then stay consistent.
When do you want your side-effect window? At work? Asleep? During training? That is the decision. Not pharmacokinetics.
Best for:
The biggest mistake in the user community. The dose-response curve flattens between 8 mg and 12 mg.
Weight Loss % at 48 weeks
That is 1.4 percentage points of additional weight loss for 50% more drug, at 50% to 100% more side effect burden.
Every GLP-1-class drug studied shows substantial weight regain after stopping. Pooled meta-analyses: about 76% of weight lost is regained, with a half-life of about 23 weeks.
Treat it like an antihypertensive. Treat it as severe metabolic disease. Stopping means reverting.
6 to 12 month cycles followed by maintenance dose tapers. Common in optimization circles.
Short focused 12 to 24 week protocols for specific metabolic goals (liver fat, lipid normalization), then off. Best for longevity-focused lean users.
This is the biggest mistake in the entire community. A 100 kg person losing 25% of body weight on retatrutide loses 25 kg total. About 5 to 7 kg of that will be lean mass. That is normal for the magnitude of weight loss. It is also avoidable.
1.2 g/kg minimum. 1.6 g/kg target. Calculate against reference body weight, not current weight. For lean users, calculate from lean body mass.
2–3 days per week. Full body or upper-lower split. Progressive overload. Without this, retatrutide produces a smaller and weaker version of you.
GI symptoms are the most common. Mostly during titration. Mostly resolve.
At higher doses
Also: constipation, heartburn, reflux.
Resting heart rate goes up 5 to 10 bpm at higher doses. Larger than semaglutide or tirzepatide (2 to 4 bpm). Mechanism: GLP-1 chronotropy plus direct glucagon-receptor effects.
For men and women on TRT, retatrutide is mechanistically the right complement.
Drives weight loss and metabolic recovery. Significant fat loss reduces aromatization, often improves T profile.
Preserves lean mass, supports recovery, maintains training. TRT dose may need to drift down if total T trends supraphysiologic.
Optimize TRT first. Get the fundamentals dialed: testosterone, thyroid, cortisol, sleep, training, protein. Then add retatrutide.
The signal is in the trend, not the day.
Weekly average, not daily. Expect 1 to 1.5% loss per week early, slowing over time.
Every 12 to 16 weeks. Fat mass should drop substantially. Lean mass should hold roughly steady or decline modestly.
12 to 16 week intervals. These are the real scorecard.
Energy, training performance, sleep quality, hunger signal.
If you choose to come off, plan the taper before you start. "I will run this for 6 months, then taper" is a plan. "I will keep going until something changes" is not.
Set a taper start date
Drop one dose every 4 weeks
Move to 2 mg weekly or stop
Things that wreck protocols. Most of these are avoidable with a plan.
8 mg works for most people. The extra 1.4% weight loss at 12 mg is not worth the side effect burden.
The drug does not protect lean mass on its own. This is the biggest one.
The scale is the worst measure of what this drug does well.
Panic kicking when weight comes back. It always comes back. Plan for it.
It is a complement, not a replacement. Sort your hormones first.
Different goals. Different doses. Different timelines.
The scale is the worst measure of what this drug does well. Track lipids, liver enzymes, HbA1c, and inflammatory markers at regular intervals.
Retatrutide is the most powerful metabolic compound available. That is true for weight loss. It is also true for every downstream metric of metabolic health. But the framework still wins.
Sorts their hormones. Trains. Eats enough protein. Uses retatrutide as a focused tool. Gets a substantially leaner, metabolically healthier version of themselves.
Treats retatrutide as a magic bullet for an unoptimized life. Gets thin. Gets disappointing labs. Has to start over.